Direxion Daily S&P Biotech Bear 3X Shares (LABD)

NYSEARCA: LABD · Real-Time Price · USD
6.63
-0.03 (-0.45%)
Aug 1, 2025, 4:00 PM - Market closed
-0.45%
Assets$58.99M
Expense Ratio1.07%
PE Ration/a
Shares Out12.92M
Dividend (ttm)$0.28
Dividend Yield4.16%
Ex-Dividend DateJun 24, 2025
Payout FrequencyQuarterly
Payout Ration/a
Volume14,738,378
Open6.83
Previous Close6.66
Day's Range6.58 - 6.97
52-Week Low4.78
52-Week High16.05
Beta-2.51
Holdings10
Inception DateMay 28, 2015

About LABD

Fund Home Page

The Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is issued by Direxion.

Asset Class Equity
Category Trading--Inverse Equity
Region North America
Stock Exchange NYSEARCA
Ticker Symbol LABD
ETF Provider Direxion
Index Tracked S&P Biotechnology Select Industry

Top 10 Holdings

100.00% of assets
NameSymbolWeight
Goldman Sachs Sterling FixInc Port Incn/a49.00%
Dreyfus Govt Cash Man Insn/a46.32%
Goldman Sachs Fin Gov 465 Institutn/a13.50%
Dreyfus Trsry Securities Cash Mgmtn/a7.81%
Cashn/a0.00%
Jpm Collateraln/a-1.04%
Baml Collateraln/a-1.81%
Citi Collateraln/a-2.75%
Goldman Collateraln/a-3.76%
S&P Biotechnology Select Industry Index Swapn/a-7.29%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Jun 24, 2025$0.03696Jul 1, 2025
Mar 25, 2025$0.05463Apr 1, 2025
Dec 23, 2024$0.12639Dec 31, 2024
Sep 24, 2024$0.05774Oct 1, 2024
Jun 25, 2024$0.08904Jul 2, 2024
Mar 19, 2024$0.0664Mar 26, 2024
Full Dividend History

Performance

LABD had a total return of 16.21% in the past year, including dividends. Since the fund's inception, the average annual return has been -49.81%.

News

LABD: An Absolute Avoid

Shorting and inverse bets don't work over time on average, making inverse funds like Direxion Daily S&P Biotech Bear 3X Shares ETF a big avoid. The LABD ETF is a triple-leveraged inverse ETF that focu...

1 year ago - Seeking Alpha

LABU And LABD: Another Attractive Double-Short Pairs Trade

Pairing Direxion Daily's S&P Biotech Bull 3X Shares ETF with their S&P Biotech Bear 3X Shares ETF produces a low volatility couple. Shorting both assets is attractive because leveraged assets erode ov...

Other symbols: LABU
2 years ago - Seeking Alpha

LABD: 3X Leveraged Inverse Fund In Biotechnology Sector Is Best Avoided

Direxion Daily S&P Biotech Bear 3X Shares ETF failed to generate decent yield & price growth over the past 90 months. I don't foresee this fund generating positive growth in the near future, either. L...

2 years ago - Seeking Alpha

May MDA Breakout Stocks/ETFs Week 20 - 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 20 with better than 10% short-term upside, ETF updates, and two Dow 30 Picks. Average cumulative returns for 2023 are +68.3% YTD. The negative MG Signal continues, but...

2 years ago - Seeking Alpha

Leveraged Biotech ETFs: Hold LABU, Sell LABD

SPDR® S&P Biotech ETF, the Biotechnology Select Industry Index ETF, has an extreme short interest of 51.16%. XBI is in an uptrend since May-June 2022. Direxion Daily S&P Biotech Bull 3X Shares ETF, th...

Other symbols: LABU
2 years ago - Seeking Alpha

MDA Breakout Stocks/ETFs Week 13 - March 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 13 with better than 10% short-term upside and a Dow 30 Pick. Average cumulative returns for 2023 are +47.4% YTD. The Momentum Gauges® continue negative in bear funds f...

2 years ago - Seeking Alpha

MDA Breakout Stocks/ETFs Week 12 - March 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 12 with better than 10% short-term upside with ETFs and a Dow 30 Pick. Average cumulative returns for 2023 are +37.3% YTD. The Momentum Gauges® continue negative in be...

2 years ago - Seeking Alpha

MDA Breakout Stocks/ETFs Week 11 - March 2023: High-Frequency Gainers To Give You An Edge

Two new Breakout Stocks for Week 11 with better than 10% short-term upside and Dow 30 Picks. Average cumulative returns for 2023 are +37.6% YTD. The Momentum Gauges® continued negative with bear funds...

2 years ago - Seeking Alpha

The Sell Rating Of LABD Is Reaffirmed

Since July 8 when I rated LABD a SELL, the underlying biotechnology index has moved very little up or down; LABD declined 25.22%. The biotechnology sector has done relatively well during the last four...

2 years ago - Seeking Alpha

LABD: A Bad Bad Drift

Leveraged ETFs have a non-linear, unpredictable behavior. A drift dashboard with 22 of them.

2 years ago - Seeking Alpha

Leveraged Biotech ETFs: Buy LABU, Sell LABD

Starting with September 2021, LABU had a record sequence of nine consecutive months with negative returns. During the biotech downtrend from September 2021 to April 2022, LABD has returned 207%.

Other symbols: LABU
3 years ago - Seeking Alpha

LABD: 3X Leveraged Investments Not Suitable For Long Term

3X inverse derivative investments are extremely volatile and risky.

3 years ago - Seeking Alpha

Biotechs Ready To Roar

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotec...

4 years ago - Seeking Alpha

Biotech Innovations Remain At Forefront

The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...

4 years ago - Seeking Alpha

Moving Beyond COVID In Biopharma

Just over one year after COVID-19 disrupted our lives, we are now getting to the point where multiple vaccine options are nearly ubiquitous for those in the United States. Per the CDC, as of April 12,...

4 years ago - Seeking Alpha